How Weight-Loss Medication Is Changing People’s Relationship With Alcohol

Weight-loss medications are changing more than eating habits. For some people taking popular GLP-1 medicines, including semaglutide and tirzepatide, an unexpected change is happening too: they are drinking less alcohol.

Medicines such as Wegovy, Ozempic and Mounjaro are primarily prescribed for weight management and, in some cases, type 2 diabetes. They work partly by reducing appetite and helping people feel fuller for longer. But researchers are increasingly interested in another possible effect: a reduction in cravings for alcohol.

For some users, the change has been dramatic.

Some people say they simply lose the desire to drink

Before starting weight-loss medication, Lisa Rees from South Wales says alcohol was an important part of her social life. She estimates that she could drink six to eight bottles of wine across a typical week.

Since starting Wegovy, however, her relationship with alcohol has changed.

Lisa says that after a couple of glasses of wine, she no longer wants another drink. Sometimes, she says, she feels physically unable to continue drinking.

What makes the change particularly significant for her is that she has not deliberately set out to stop drinking. Instead, the medication appears to have changed how much she wants.

She says this has allowed her to continue participating in social occasions without drinking the amount she once did.

Her experience is not unique.

Other people taking GLP-1 medications have described experiencing lower alcohol cravings, feeling full or nauseous after drinking, or becoming intoxicated after smaller amounts than they were previously accustomed to.

However, not everyone notices a change.

Why might GLP-1 drugs affect alcohol cravings?

Scientists are still trying to understand exactly why these medications may influence drinking behaviour.

GLP-1 receptor agonists mimic the effects of a naturally occurring hormone called glucagon-like peptide-1. These medicines are known to influence appetite and food intake, but GLP-1 receptors are also involved in areas of the brain associated with reward and motivation.

That has led researchers to investigate whether the medications could influence cravings for substances such as alcohol and nicotine.

Early research is encouraging, although it is still developing.

A 2025 randomised clinical trial published in JAMA Psychiatry examined semaglutide in adults with alcohol use disorder. The study involved only 48 participants, so it was relatively small, but researchers found that semaglutide reduced alcohol consumption during a laboratory drinking session and reduced weekly alcohol craving compared with placebo. The researchers said the findings support the need for larger clinical trials.

Other research has also found associations between GLP-1 medication use and lower alcohol-related risks. A large Swedish observational study involving people diagnosed with alcohol use disorder found that semaglutide and liraglutide were associated with lower risks of alcohol-related hospitalisation. Importantly, observational research cannot prove that the medication itself caused the reduction.

This distinction matters.

There is a growing scientific interest in GLP-1 medicines and alcohol, but researchers are not yet saying that weight-loss injections should be regarded as an established treatment for alcohol addiction.

Drinking less can also support weight-loss goals

There is another obvious connection between alcohol and weight management.

Alcohol contains calories, and alcoholic drinks can also make it easier to consume more food than planned. Reducing alcohol intake can therefore complement the dietary changes people make while taking weight-loss medication.

UK health guidance recommends that adults should not regularly drink more than 14 units of alcohol per week. That is roughly equivalent to six medium glasses of wine or six pints of beer, although the exact number of units varies depending on the strength and size of a drink.

For someone who previously drank substantially more than this, a reduction in alcohol consumption could make a meaningful difference to overall calorie intake.

But the potential benefits are not only about weight.

Regularly drinking too much alcohol can increase the risk of a range of health problems, including liver disease, high blood pressure and certain cancers.

For some people, the change can make socialising harder

While drinking less may be welcome for some, it is not necessarily an entirely positive experience for everyone.

Faye Goodwin, a young adult who has taken Mounjaro, says alcohol can quickly make her feel nauseous. She has also experienced acid reflux and vomiting.

For her, the issue is particularly difficult because alcohol can be closely connected to socialising among young adults.

She says there have been occasions when she has avoided going out because she knew the medication could make drinking unpleasant. When she does attend social events, she often drinks considerably less than her friends.

This highlights an important part of the conversation that can easily be overlooked.

Changing your relationship with alcohol is not simply about the number of drinks in a week. For some people, drinking is connected to friendships, celebrations, dating, university life and social identity.

If medication changes someone's ability or desire to drink, it can also change how they experience those situations.

Some people notice a lower alcohol tolerance

Another common experience reported by some users is that alcohol appears to affect them more quickly.

Warren Thomas from Colchester says he previously enjoyed occasional beers with his family and heavier drinking sessions with friends.

After starting Mounjaro, he says his desire to drink largely disappeared. On one occasion, two beers left him feeling light-headed and giddy.

He now describes his tolerance as effectively being zero.

Experiences like this are important because people should not assume that their previous drinking habits will feel the same after starting medication.

Feeling different after a smaller amount of alcohol may be a reason to slow down, drink less or avoid alcohol altogether.

Could these medicines eventually be used to treat alcohol addiction?

This is one of the biggest questions researchers are investigating.

The early evidence has generated interest in using GLP-1 medicines for alcohol use disorder, as well as potentially for other forms of addiction.

However, more research is needed before these medicines can be considered an established treatment for alcohol use disorder.

The 2025 clinical trial was small, while some other research has been observational. Larger studies involving more people and longer follow-up periods are needed to establish how effective these medicines are, who might benefit and whether the potential benefits outweigh the risks.

Researchers are also examining whether GLP-1 medications could affect cravings for other substances, including nicotine and opioids.

A changing relationship with alcohol

For people taking weight-loss medication, drinking less alcohol may be an unexpected side effect rather than the main reason they started treatment.

For some, it can feel like a welcome change. They may save money, consume fewer calories and reduce their exposure to alcohol-related health risks without having to make a conscious decision to quit drinking.

For others, however, the change can create social challenges, particularly when alcohol plays a major role in their friendships or social routines.

The science is still evolving, but one thing is becoming increasingly clear: the effects of GLP-1 medications may extend beyond food and appetite.

As researchers continue to investigate how these medicines interact with the brain's reward system, their potential influence on alcohol cravings could become an important area of medical research.

For now, anyone taking a GLP-1 medication should discuss concerns about alcohol, side effects or changes in drinking habits with a healthcare professional rather than assuming that experiences reported by other users will apply to them.

Sources: JAMA Psychiatry on semaglutide and alcohol use disorder, together with UK NHS guidance on alcohol consumption.

Disclaimer: This article is for general information only and is not medical advice. Weight-loss medicines are prescription treatments and can have side effects and risks. Do not change your medication dose, delay an injection or stop treatment because of alcohol-related concerns without speaking to a qualified healthcare professional. If you are concerned about your alcohol consumption or possible alcohol dependence, seek advice from a doctor or an appropriate alcohol support service.